A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; ...

Chief Scientific Officer Dr. Daniel Skovronsky talked with the IBJ about his hopes for the Lilly Medicine Foundry, which the ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies.

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Industry veteran Charmaine Lykins to helm Transneural as it transforms the treatment of neuropsychiatric disorders ISSAQUAH, WASHINGTON / ACCESS Newswire / April 22, 2025 / CaaMTech, Inc. has spun out ...

"the oral GLP-1 inhibitor that we've been developing for more than eight years. And the results are exciting." On Thursday, Eli Lilly released data on Phase 3 trials of an experimental, daily ...

While Eli Lilly has a significant presence in the U.S., bringing its developing treatment to market will require stable business conditions. The Indianapolis company on Thursday said its ...